xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

320

KUANetal.

TABLE XXVI.3 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Michot et al. 1901

1. 2-year survival was 72% 2. 92% experienced grade 2 or 3 neutropenia

1. OS 2. Adverse side effects

2015 4

Retrospective case series

13 patients treated at a single institution (all stage IE or IIE) treated with two cycles of ESHAP and RT (40 Gy dose), followed by consolidation dose of two to three rounds of ESHAP Three patients with ENKTL treated at a single institution; two treated with CHOP (and RT), one had CHOP (two rounds) but passed away prior to completing treatment ENKTL treated at a single institution 10 received CRT and nine received chemotherapy alone Several chemotherapy regimens included, with some including 23 patients with treated at a single center; 138 treated with anthracycline chemotherapy (with or without RT), 60 patients nonanthracycline (IMEP, SMILE, or VIPD) regimens, five RT only, and five supportive care early-stage sinonasal ENKTL (stage IE or IIE); 23 treated with RT and 41 treated with CRT using anthracycline-based chemotherapy 64 patients with etoposide and asparaginase 208 ENKTL patients

Cohaet al. 1849

2014 4

Retrospective case series

OS

Anthracycline regimens (e.g., CHOP) are insufficient for disease control

Youssef et al. 1902 2012 4

OS

Study noted resistance to asparaginase-based protocols

Retrospective case series

Kimet al. 1855

2010 4

Retrospective case series

Development of CNS disease

1. 12 patients developed CNS disease (5.76%) 2. ENKTL international prognostic index groups I and II do not need CNS prophylaxis, while III and IV should receive it

Maet al. 1853

1. OS 2. PFS

1. 5-year OS for RT was 57.9% and CRT was 61.5%, no significant difference between treatments 2. Chemotherapy does not improve survival in early-stage disease

2010 4

Retrospective case series

(Continues)